IMMU-106

IMMU-106 is a monoclonal antibody designed to target CD20, a protein found on the surface of B cells. It is being developed by Immunomedics, a biopharmaceutical company, for the treatment of non-Hodgkin lymphoma and autoimmune diseases.

Mechanism of Action

IMMU-106 works by binding to CD20, a protein found on the surface of B cells. This binding triggers a process known as antibody-dependent cellular cytotoxicity (ADCC), in which immune cells are recruited to kill the B cells. This can help to reduce the number of harmful B cells in the body, potentially reducing the symptoms of diseases such as non-Hodgkin lymphoma and autoimmune diseases.

Clinical Trials

IMMU-106 has been tested in several clinical trials. In a phase I/II trial, the drug was found to be safe and well-tolerated, with some patients showing a response to treatment. Further trials are needed to confirm these results and to determine the optimal dosing regimen.

Potential Uses

IMMU-106 is being developed for the treatment of non-Hodgkin lymphoma, a type of cancer that affects the lymphatic system. It is also being investigated for use in treating autoimmune diseases, conditions in which the body's immune system mistakenly attacks its own cells.

See Also

• Monoclonal antibodies
• CD20
• Non-Hodgkin lymphoma
• Autoimmune diseases
• Immunomedics
• Clinical trials

IMMU-106 Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.